Sanofi’s plan to become a dominant player in the respiratory syncytial virus (RSV) market has moved a step closer, with FDA approval of Beyfortus for the prevention of RSV disease in infants.

It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...

Yun Ki-wook, a professor in SNUH's Department of Pediatric Infectious Diseases, discusses the domestic release of Beyfortus, an antibody treatment for respiratory syncytial virus, during a press ...

Pfizer's maternal vaccine, sold as Abrysvo, and Sanofi and AstraZeneca's antibody shot, Beyfortus, are available in the ...

Far fewer babies had severe cases of the respiratory illness RSV, in a winter in which a new monoclonal and vaccine became ...

Dr Reddy’s Laboratories expands its strategic partnership with Sanofi Healthcare India to introduce a novel drug, Beyfortus (nirsevimab), in India. Beyfortus contains the monoclonal antibody, ...

Against the backdrop of World Immunization Week, Dr Reddy’s Laboratories Ltd and Sanofi Healthcare India have expanded their partnership to bring in Beyfortus – a novel drug to prevent ...

Beyfortus, which has been approved for use in the European Union, US, China, Japan, among several countries globally, received its marketing authorisation approval from India’s Central Drugs ...

This was driven by launches, Dupixent, and favorable Beyfortus phasing. Sales increased 10.8% year over year and 9.7% on constant currency. U.S. sales were 4.66 billion and increased by 15.4%.

Pfizer's maternal vaccine, sold as Abrysvo, and Sanofi and AstraZeneca's antibody shot, Beyfortus, are available in the United States to prevent RSV infection in infants. The largest estimated ...